PloS one

Predicting Attention and Thinking Skills Using Self-Reported Alertness, Body Clock, Time Awake, and Sleep Loss

Updated

Abstract

is the best predictor of performance on cognitive tasks but is insufficient on its own.

  • Impaired cognitive performance may result from sleep restriction in occupational settings.
  • Healthy young adults participated in a forced desynchrony schedule involving twelve 42.85-hour 'days.'
  • Subjective alertness measured on a visual analog scale was the strongest predictor for performance on the Psychomotor Vigilance Task, Addition/Calculation Test, and Digit Symbol Substitution Test.
  • Subjective alertness alone was not an accurate predictor of performance on the Psychomotor Vigilance Task.
  • Including , hours since awakening, and cumulative sleep loss improved the prediction of objective performance.

Simplified

Key numbers

50 hours
Cumulative Sleep Loss
Cumulative lost hours of sleep by the end of the forced desynchrony protocol.
1511±2106 ms
PVT Reaction Time
Mean reaction time for the Chronic Sleep Restriction group in the last week of the study.

Full Text

What this is

  • Sleep loss negatively impacts cognitive performance, particularly in high-stakes occupations.
  • This research examines how self-reported alertness correlates with objective cognitive performance under varied sleep conditions.
  • Healthy young adults participated in forced desynchrony protocols to assess the predictive power of , , wake duration, and on cognitive tasks.

Essence

  • is the best predictor of cognitive performance, but alone is insufficient. Including , wake duration, and cumulative sleep loss improves predictions.

Key takeaways

  • alone is a weak predictor of performance on cognitive tasks like the Psychomotor Vigilance Task (PVT). Including additional factors enhances prediction accuracy.
  • and cumulative sleep loss significantly influence cognitive performance. Models that incorporate these factors alongside provide better predictions.

Caveats

  • Participants may not accurately assess their cognitive performance due to the brief nature of ratings, which could lead to underestimations of impairment.
  • The study relied on scheduled sleep opportunities rather than actual sleep duration, which might not reflect true experienced by participants.

Definitions

  • Subjective Alertness: Self-reported perception of one's alertness level, typically rated on a scale.
  • Circadian Phase: The biological timing of an individual’s internal clock, affecting alertness and performance.
  • Sleep Debt: The cumulative effect of not getting enough sleep, impacting cognitive performance.

Simplified

Funding

Competing interests

Competing Interests: The authors of this manuscript have the following competing interests: Dr. Klerman has received travel funds from Servier and the Sleep Technology Council. Dr. Phillips has consulted for Zeo, Inc. Dr. Wyatt has consulted for Phillips-Respironics. Dr. Czeisler has received consulting fees from: Amazon.com, Inc.; A2Z Development Center; Bose Corporation; Boston Celtics; Boston Red Sox; Cephalon, Inc.; Citgo Inc.; Cleveland Browns; Columbia River Bar Pilots; Jazz Pharmaceuticals; Koninklijke Philips Electronics, N.V.; Minnesota Timberwolves; Portland Trail Blazers; Samsung Electronics; Teva Pharmaceuticals; Valero Inc.; Vanda Pharmaceuticals. Dr. Czeisler has also received education/research support from Mary Ann & Stanley Snider via Combined Jewish Philanthropies, Philips Respironics, San Francisco Bar Pilots, and Vanda Pharmaceuticals, Inc. Dr. Czeisler is the incumbent of an endowed professorship provided to Harvard University by Cephalon, Inc. and holds a number of process patents in the field of sleep/circadian rhythms. Since 1985, Dr. Czeisler has also served as an expert on various legal cases related to sleep and/or circadian rhythms including those involving the following commercial entities: Bombardier, Inc.; Continental Airlines; FedEx; Greyhound; Purdue Pharma, L.P.; and United Parcel Service (UPS). Dr. Czeisler owns or owned an equity interest in Somnus Therapeutics, Inc. and Vanda Pharmaceuticals. He received royalties from Houghton Mifflin Harcourt/Penguin Press, and Philips Respironics, Inc. for the Actiwatch-2 and Actiwatch-Spectrum devices. Dr. Czeisler’s interests were reviewed and managed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free